Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app

Tandem Diabetes Care mobile bolus user and professional skier Lauren Salko with her Tandem mobile bolus app. [Image from Tandem Diabetes Care]Tandem Diabetes Care (Nasdaq:TNDM) announced today that its users have delivered more than 1 million insulin boluses using its app.

Users of the t:connect app feature on their personal mobile device have reached the 1 million insulin bolus milestone with the t:slim X2 insulin pump within the first month following its commercial release.

San Diego-based Tandem designed the t:connect mobile app to offer users of the t:slim X2 insulin pump the ability to program and cancel bolus insulin requests through the convenience of their compatible smartphone. The company said in a news release that it is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems. The company added that it is now available on approximately 30 different devices.

Read more

  • 0

Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Image from Tandem Diabetes

Wells Fargo downgraded Tandem Diabetes Care (Nasdaq:TNDM) as competitors apply pressure to the automated insulin delivery technology developer.

According to SeekingAlpha, analysts led by Larry Biegelsen moved Tandem from “Overweight” to “Underweight” due to bullish expectations on Wall Street as the company’s competition, including Insulet and Medtronic, come to the fore. The street responded in kind, with shares of TNDM down 6.8% at $56 per share in early-morning trading today.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Tandem sinks on Q2 misses, slashed sales guidance

Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast.

Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results.

The San Diego-based automated insulin delivery technology developer posted losses of $15.1 million, or 24¢ per share, on sales of $200.3 million for the three months ended June 30, 2022, for a roughly $20 million bottom-line slide into the red on sales growth of 16.3%.

On Wall Street, analysts had been looking for sales of $205.3 million and adjusted earnings per share of 2¢.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Tandem Diabetes Care adds two new members to its board

Image from Tandem Diabetes

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors.

Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday, June 15, 2022.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions

For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space.

Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table.

The data showcased at ADA supported the usual continuous glucose monitoring (CGM) and automated insulin delivery (AID) technology, plus different digital health platforms and diabetes reversal procedures.

BTIG analyst Marie Thibault wrote in a report that there was plenty of buzz on the ground at the event, particularly around Insulet’s Omnipod 5 AID system, Abbott’s recently FDA-cleared FreeStyle Libre 3 CGM and Bigfoot Biomedical’s Bigfoot Unity platform.

“In general, we believe that accuracy and clinical benefit is proven for all commercial CGM and AID offerings an…

Read more
  • 0

Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology

Image from Tandem Diabetes

Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology.

Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Tandem dips after hours after Q1 EPS miss despite revenue beat, raised guidance

Image from Tandem Diabetes

Tandem Diabetes Care (Nasdaq:TNDM) shares slid slightly after hours today on first-quarter results that were mixed compared to the consensus forecast.

The San Diego-based automated insulin delivery technology developer posted losses of $14.7 million, or 23¢ per share, on sales of $175.9 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red despite sales growth of 24.7%.

Losses per share of 23¢ for Tandem came in 16¢ behind projections on Wall Street, where analysts were looking for sales of $168.43 million.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

 

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

 

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Real-world evidence shows Tandem’s t:slim X2 insulin pump improves outcomes

Image from Tandem Diabetes

Tandem Diabetes Care (Nasdaq:TNDM) announced real-world data confirming positive outcomes with its t:slim X2 insulin pump.

Data demonstrated that the t:slim X2 pump with Control-IQ advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes and user-reported reduced burden of diabetes management.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Diabetes tech is off to a hot start in 2022

Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition.

Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.

Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Diabetes tech is off to a hot start in 2022

Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition.

Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.

Expectations were already high for new technology coming out of the diabetes space, and significant improvements last year only lifted those hopes higher. Let’s check in with a few companies promising big steps forward, including some that have already made significant progress.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Tandem Diabetes warns on some t:slim X2 insulin pumps

Tandem Diabetes Care (Nasdaq:TNDM) issued an urgent field safety notice in Europe for its t:slim X2 insulin pump with Basal-IQ technology.

The notice, dated February 2022, alerts users of Tandem’s insulin pump with a software version of 6.3.0.1 that there may be a potential safety risk when using the pump within its normal specifications. Tandem’s t:slim X2 with Control-IQ technology is not affected.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0